<DOC>
	<DOCNO>NCT01192308</DOCNO>
	<brief_summary>All woman tamoxifen receive standard dose 20mg QD , irrespective use potential CYP2D6 inhibitor , test CYP2D6 polymorphism prior start tamoxifen treatment.However CYP2D6 polymorphism and/or use CYP2D6 inhibitor co-medication may influence treatment outcome tamoxifen . The investigator propose prospective study woman take tamoxifen dose 20mg QD . In woman , information collect endoxifen level , CYP2D6 status , adherence use co-medication . In woman phenotypically poor metabolizers tamoxifen , dose increase 40mg QD apply effect intervention tamoxifen pharmacokinetics evaluate 4 week .</brief_summary>
	<brief_title>PharmacoKINEtics TAMoxifen Its Metabolites Breast Cancer Patients : Influence Dose Increase Phenotypic Poor Metabolizers CYP2D6 ( KINETAM )</brief_title>
	<detailed_description>Although already information available importance CYP2D6 polymorphism and/or use CYP2D6 inhibitor co-medication may influence treatment outcome tamoxifen , information currently lead change management patient population . All woman tamoxifen receive standard dose 20mg QD , irrespective use potential CYP2D6 inhibitor , test CYP2D6 polymorphism prior start tamoxifen treatment . In attempt least resolve issue propose prospective study woman take tamoxifen dose 20mg QD follow several large oncology clinic south-eastern part Netherlands ( Nijmegen ( CWZ &amp; Radboud ) , Den Bosch , Harderwijk Arnhem ) . In woman , information collect endoxifen level , CYP2D6 status , adherence use co-medication . In woman phenotypically poor metabolizers tamoxifen , dose increase 40mg QD apply effect intervention tamoxifen pharmacokinetics evaluate 4 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Subject least 18 year screen . Subject able willing sign Informed Consent Form prior screen evaluation . Subject female patient ( history ) breast cancer treat tamoxifen 20mg QD least 4 week expect treat least another 4 week Inability understand nature extent trial procedure require . Participation drug trial within 60 day prior first dose .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Tamoxifen</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacogenetics</keyword>
	<keyword>CYP2D6</keyword>
</DOC>